作者: Karen Antman , John Crowley , Stanley P Balcerzak , Saul E Rivkin , Geoffrey R Weiss
DOI: 10.1200/JCO.1993.11.7.1276
关键词: Ifosfamide 、 Bone Sarcoma 、 Mesna 、 Surgery 、 Internal medicine 、 Chemotherapy 、 Rhabdomyosarcoma 、 Oncology 、 Doxorubicin 、 Dacarbazine 、 Sarcoma 、 Medicine
摘要: PURPOSE AND METHODSDoxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas. Ifosfamide active in sarcomas that have failed to respond a doxorubicin-based regimen. This study was designed determine if ifosfamide added doxorubicin and DTIC (ADI) significantly effects toxicity, response rate, survival. Patients measurable unresectable sarcoma were randomized receive AD ADI. chondrosarcomas, fibrosarcomas, other of bone eligible, although those osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma, Kaposi's mesothelioma excluded, as patients prior chemotherapy doxorubicin.RESULTSBetween 1987 1989, 340 eligible randomized. Significantly more myelosuppression, higher rate (17% v 32%; P < .002) longer time progression (4 6 months; .02) observed who received ifosfamide. An...